Silenseed Announces FDA Orphan Designation of siG12D-LODER Drug/Treatment.

Jerusalem, January 26 2015 – Silenseed LTD announces the receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for KRAS-LODER for treatment of pancreatic cancer. “The Orphan Drug designation of KRAS-LODER for the treatment of pancreatic cancer is Silenseed’s first RNAi-based treatment regulatory submission” said Dr. Amotz Shemi, CEO of Silenseed. “We’ve completed […]